Shah Gull
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shah Gull has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Aleena Gul
Department of Bioinformatics and Biosciences Capital University of Science and Technology Islamabad Pakistan
1 shared publicationAqsa Qasim Zafar
Department of Bioinformatics and Biosciences Capital University of Science and Technology Islamabad Pakistan
1 shared publication- Aqsa Qasim Zafar
Department of Bioinformatics and Biosciences Capital University of Science and Technology Islamabad Pakistan
1 shared publication Farhana Mansoor
Department of Bioinformatics and Biosciences Capital University of Science and Technology Islamabad Pakistan
1 shared publicationHafsa Arshad
Department of Bioinformatics and Biosciences Capital University of Science and Technology Islamabad Pakistan
1 shared publication- Hafsa Arshad
Department of Bioinformatics and Biosciences Capital University of Science and Technology Islamabad Pakistan
1 shared publication
Latest Publications
- 3 September 2026
- Published by Wiley in Biotechnology and Applied Biochemistry
A Comprehensive Review of Exopolysaccharides From Lactic Acid Bacteria: Production, Characterization, and Applications in Food and Health
Lactic acid bacteria (LAB) produce exopolysaccharides (EPSs), which are beneficial in food and health applications because of their varied structural and functional characteristics. These EPSs are attracting a lot of interest. Homopolysaccharides (HoPSs) and heteropolysaccharides (HePSs) are two types of LAB‐derived EPS that differ in their monosaccharide compositions and physicochemical properties. These biopolymers are produced through processes, such as extracellular synthesis and Wzx/Wzy‐dependent mechanisms, which are controlled by environmental and genetic variables like pH, temperature, fermentation duration, and carbon‐to‐nitrogen ratios. In dairy products, like yogurt and cheese, EPS improves texture, moisture retention, and shelf life by acting as natural thickeners, stabilizers, and emulsifiers. They are also perfect for clean‐label formulations due to their biocompatibility and biodegradability. In addition to its use in food, EPS has anticancer, antioxidant, immunomodulatory, cholesterol‐lowering, and antidiabetic benefits. They alter gut microbiota, enhance intestinal health, and interact with immunological receptors (such as toll‐like receptors [TLRs]). Furthermore, EPS exhibits promise in medicinal applications like biofilm inhibition, wound healing, and drug delivery systems. Large‐scale applications are restricted by issues including low yield and high manufacturing costs, notwithstanding their potential. To overcome these obstacles, developments in genetic engineering and fermentation optimization are essential. The biosynthesis, structural variety, and multifunctional roles of LAB‐EPS in food innovation and health promotion are highlighted in this review, which also highlights future research areas to increase their industrial and therapeutic value.
- 3 September 2026
- Published by Wiley in Biotechnology and Applied Biochemistry
A Comprehensive Review of Exopolysaccharides From Lactic Acid Bacteria: Production, Characterization, and Applications in Food and Health
Lactic acid bacteria (LAB) produce exopolysaccharides (EPSs), which are beneficial in food and health applications because of their varied structural and functional characteristics. These EPSs are attracting a lot of interest. Homopolysaccharides (HoPSs) and heteropolysaccharides (HePSs) are two types of LAB‐derived EPS that differ in their monosaccharide compositions and physicochemical properties. These biopolymers are produced through processes, such as extracellular synthesis and Wzx/Wzy‐dependent mechanisms, which are controlled by environmental and genetic variables like pH, temperature, fermentation duration, and carbon‐to‐nitrogen ratios. In dairy products, like yogurt and cheese, EPS improves texture, moisture retention, and shelf life by acting as natural thickeners, stabilizers, and emulsifiers. They are also perfect for clean‐label formulations due to their biocompatibility and biodegradability. In addition to its use in food, EPS has anticancer, antioxidant, immunomodulatory, cholesterol‐lowering, and antidiabetic benefits. They alter gut microbiota, enhance intestinal health, and interact with immunological receptors (such as toll‐like receptors [TLRs]). Furthermore, EPS exhibits promise in medicinal applications like biofilm inhibition, wound healing, and drug delivery systems. Large‐scale applications are restricted by issues including low yield and high manufacturing costs, notwithstanding their potential. To overcome these obstacles, developments in genetic engineering and fermentation optimization are essential. The biosynthesis, structural variety, and multifunctional roles of LAB‐EPS in food innovation and health promotion are highlighted in this review, which also highlights future research areas to increase their industrial and therapeutic value.
- 10 November 2025
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 73 (3) , 1611-1625
A Comprehensive Review on Engineering Lactic Acid Bacteria: Emerging Genetic Tools and Synthetic Biology Strategies
Lactic acid bacteria (LAB) are pivotal in food, pharmaceutical, and environmental applications due to their metabolic versatility and probiotic potential. This review explores the advancements in genetic engineering and synthetic biology strategies to enhance LAB functionality. We examine the genomic architecture of key LAB species, such as Lactobacillus and Lactococcus , highlighting their natural genetic traits and metabolic constraints. Emerging genetic tools, including electroporation, conjugation, and CRISPR‐Cas systems, have revolutionized LAB modification, enabling precise gene editing and expression control. Synthetic biology approaches, such as genetic circuits, riboswitches, and biosensor development, offer novel pathways for optimizing LAB for functional foods, mucosal therapeutics, and industrial biotechnology. We discuss applications in probiotic delivery, bioremediation, and agricultural enhancement, emphasizing LAB's role in producing bioactive metabolites and combating pathogens. Challenges, including plasmid instability, metabolic burden, and regulatory hurdles, are addressed alongside socio‐ethical considerations for genetically modified LAB. The integration of genome‐scale engineering and CRISPR‐based technologies holds promise for overcoming these barriers, paving the way for next‐generation LAB with enhanced stress tolerance and tailored functionalities. This review synthesizes current knowledge and future prospects, underscoring the transformative potential of engineered LAB in addressing global health, environmental, and industrial needs while navigating biosafety and public perception challenges.
- 10 November 2025
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 73 (3) , 1611-1625
A Comprehensive Review on Engineering Lactic Acid Bacteria: Emerging Genetic Tools and Synthetic Biology Strategies
Lactic acid bacteria (LAB) are pivotal in food, pharmaceutical, and environmental applications due to their metabolic versatility and probiotic potential. This review explores the advancements in genetic engineering and synthetic biology strategies to enhance LAB functionality. We examine the genomic architecture of key LAB species, such as Lactobacillus and Lactococcus , highlighting their natural genetic traits and metabolic constraints. Emerging genetic tools, including electroporation, conjugation, and CRISPR‐Cas systems, have revolutionized LAB modification, enabling precise gene editing and expression control. Synthetic biology approaches, such as genetic circuits, riboswitches, and biosensor development, offer novel pathways for optimizing LAB for functional foods, mucosal therapeutics, and industrial biotechnology. We discuss applications in probiotic delivery, bioremediation, and agricultural enhancement, emphasizing LAB's role in producing bioactive metabolites and combating pathogens. Challenges, including plasmid instability, metabolic burden, and regulatory hurdles, are addressed alongside socio‐ethical considerations for genetically modified LAB. The integration of genome‐scale engineering and CRISPR‐based technologies holds promise for overcoming these barriers, paving the way for next‐generation LAB with enhanced stress tolerance and tailored functionalities. This review synthesizes current knowledge and future prospects, underscoring the transformative potential of engineered LAB in addressing global health, environmental, and industrial needs while navigating biosafety and public perception challenges.